A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Akiko Kada, Reiji Fukano, Tetsuya Mori, Michi Kamei, Fumiko Tanaka, Junichi Ueyama, Masahiro Sekimizu, Tomoo Osumi, Takeshi Mori, Yuhki Koga, Kentaro Ohki, Naoto Fujita, Tetsuo Mitsui, Akiko M. Saito, Hiroya Hashimoto, Ryoji Kobayashi

研究成果: Contribution to journalArticle査読

抄録

No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

本文言語英語
ページ(範囲)89-94
ページ数6
ジャーナルActa medica Okayama
74
1
出版ステータス出版済み - 2020
外部発表はい

All Science Journal Classification (ASJC) codes

  • 生化学、遺伝学、分子生物学(全般)

フィンガープリント

「A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル